Welcome to our dedicated page for Dupont De Nemours SEC filings (Ticker: DD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DuPont de Nemours (NYSE: DD) sits at the intersection of chemistry and cutting-edge materials, which means its 10-K isn鈥檛 just any annual report鈥攊t鈥檚 a roadmap to Kevlar庐 liability reserves, semiconductor material demand, and water-filtration margins. If you need DuPont insider trading Form 4 transactions or a deep dive into remediation costs, every data point starts here.
Stock Titan鈥檚 AI engine turns dense disclosures into clear insights. Compare segments in the DuPont quarterly earnings report 10-Q filing, follow DuPont Form 4 insider transactions real-time, and get DuPont SEC filings explained simply without wading through footnotes. Our platform delivers:
- AI-powered summaries flagging revenue drivers, environmental accruals, and pension assumptions
- AG真人官方-time alerts on 8-K updates鈥�DuPont 8-K material events explained as they hit EDGAR
- Side-by-side DuPont earnings report filing analysis for sequential quarter trends
- Instant access to DuPont executive stock transactions Form 4 and historical patterns
Whether you鈥檙e understanding DuPont SEC documents with AI to gauge raw-material inflation or reviewing a DuPont proxy statement executive compensation vote, you鈥檒l find every form in one place. From a DuPont annual report 10-K simplified breakdown of cash flows to automated red-flag detection inside footnotes, analysts, portfolio managers, and corporate researchers save hours and make decisions with confidence.
Huron Consulting Group (HURN) 鈥� Form 4: Director John McCartney sold 500 common shares on 08/01/2025 at $129.11, realizing roughly $64.6k. The transaction was executed under a Rule 10b5-1 plan adopted 08/15/2024. After the sale, McCartney holds 51,317 shares, so the disposition equals about 1% of his personal stake and less than 0.3% of HURN鈥檚 ~20.4 m shares outstanding. No derivative positions were reported or changed. Given its small size and pre-planned nature, the filing is unlikely to have a material impact on the company鈥檚 valuation but does update insider-trading logs.
Smith & Nephew (NYSE:SNN) posted another solid period in its 6-K.
- Q2 2025 revenue rose to $1.553 bn, +7.8% reported (+6.7% underlying); H1 revenue reached $2.961 bn, +4.7% reported (+5.0% underlying) despite two fewer trading days.
- H1 trading profit climbed 11.2% to $523 m; trading margin widened 100 bps to 17.7%, while operating profit jumped 30.6% to $429 m.
- Free cash flow surged to $244 m (H1 2024: $39 m) on 93% cash-conversion; net debt/adj. EBITDA stands at 1.8脳.
- Interim dividend increased 4.2% to 15.0垄 per share and a $500 m share-buyback was announced for H2 2025.
- FY 2025 outlook unchanged: ~5% underlying revenue growth (5.5% reported) and 19-20% trading margin, absorbing a $15-20 m tariff hit.
Growth was broad-based: Orthopaedics +5.0% underlying, Sports Medicine & ENT +5.7%, Advanced Wound Management +10.2%. Recent product launches generated 75% of H1 growth, and the 12-Point Plan cut inventory by $69 m (-46 DSI days). Orthopaedics margin improved 230 bps; Advanced Wound margin +160 bps.
Key risks: China VBP pressure, Emerging-Markets H1 underlying 鈭�0.9%, potential 2026 Medicare changes to skin substitutes, higher trading-tax rate (19.8% vs. 17.8%) and $15-20 m tariff headwind. Nonetheless, operational gains and balance-sheet strength underpin continued cash returns.
On 3 Aug 2025 DuPont (NYSE: DD), Chemours and Corteva agreed to a Judicial Consent Order with the State of New Jersey to resolve all outstanding state claims tied to historic DNAPL, solvent and PFAS contamination at four legacy DuPont sites (Chambers Works, Parlin, Pompton Lakes, Repauno) and alleged statewide PFAS impacts.
Financial terms:
- A combined $875 million cash payment spread over 25 years; first instalment due no sooner than 31 Jan 2026.
- DuPont鈥檚 share is estimated at $311 million NPV; a $177 million pre-tax charge was recorded in Q2-25 discontinued operations.
- DuPont will apply its existing $35 million MOU escrow to the 2026 payment.
- DuPont & Corteva will post a separate $475 million surety-backed Reserve Fund to backstop remediation once site-level funding is exhausted.
Additional provisions: DuPont/Corteva will pay $150 million (DuPont $106.5 m) to buy Chemours鈥� rights to equal PFAS-related insurance proceeds plus a contingent fee. A third-party review could require higher remedial funding sureties, potentially increasing future environmental reserves. Parties may prepay at the settlement discount rate.
The agreement contains no admission of liability, remains subject to public comment and Federal District Court approval, and will offset each party鈥檚 annual PFAS MOU escrow obligations.
FAQ
What is the current stock price of Dupont De Nemours (DD)?
What is the market cap of Dupont De Nemours (DD)?
What is the core business of DuPont?
In which industries does DuPont operate?
How does DuPont generate revenue?
What distinguishes DuPont鈥檚 approach to innovation?
How does DuPont ensure product quality and reliability?
What role does sustainability play in DuPont鈥檚 business model?
How does DuPont maintain its competitive edge?
What are some key products associated with DuPont?
